Zentalis Pharmaceuticals, Inc. (ZNTL) Form 8-K — May 12, 2026
Zentalis Pharmaceuticals, Inc. announced its first quarter 2026 financial results, reporting a cash position of $211.8 million as of March 31, 2026, compared to $245.9 million as of December 31, 2025. The company believes this cash position will be sufficient to fund its operations into late 2027. The company also reported positive clinical progress, including the selection of 400mg QD 5:2 as the pivotal study dose for azenosertib monotherapy in Cyclin E1-positive platinum-resistant ovarian cancer (PROC) based on favorable benefit-risk profile.
Key figures
- Eps Beat
- 0
- Revenue
- 0
- Total Debt
- 70386
- Debt Amount
- 0
- Revenue Yoy
- 0
- Total Assets
- 253066
- Deal Value Usd
- 0
- Interest Rate
- 0
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- 300mg QD 5:2 ORR
- 22.2
- 400mg QD 5:2 ORR
- 33.8
- 300mg QD 5:2 m DOR
- 3.9
- 400mg QD 5:2 m DOR
- 5.5
Price after filing
Close on the filing date to close N calendar days later (from $4.28). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.